Skip to main content
Clinical Trials/NCT01505985
NCT01505985
Terminated
Phase 3

Effect of a Nutritional Intervention on Hip Fracture Surgery Recovery

Société des Produits Nestlé (SPN)1 site in 1 country24 target enrollmentJanuary 2012
ConditionsHip Fracture

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Hip Fracture
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
24
Locations
1
Primary Endpoint
The Short Physical Performance Battery (SPPB)
Status
Terminated
Last Updated
12 years ago

Overview

Brief Summary

Senior hip fracture patients are the most vulnerable to malnutrition and protein deficiency. Low protein intake, like vitamin D deficiency, contribute to an increased risk for hip fracture. Notably, several clinical trials with protein supplementation in senior hip fracture patients resulted in fewer deaths, shorter hospital stay, and a higher likelihood of return to independent living. The proposal is to test the effect of an oral nutritional supplement (ONS) which has been designed to meet the specific nutrient needs of senior bone and muscle health. The hypothesis is that this ONS will improve functional recovery after hip fracture (as measured by Short Physical Performance Battery (SPPB)), improve quality of life, improve muscle mass, and- decrease falls and hospital re-admission after hip fracture.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
September 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age (70+);
  • Had an acute hip fracture and surgical treatment
  • Able to walk at least 3 meters without assistance of another person, with or without a walking aid other than a wheeled walker prior to hip fracture MMSE \>=18 (proxy will be informed in addition if MMS-score ≤ 24)
  • Able to perform the SPPB at baseline
  • No prior hip fracture
  • Patient (and/or his/her legal representatives/relatives) understands the study procedure, alternative treatments available and risks involved with the study, and voluntarily agrees to participate by giving his/her (or his/her legal representative's/relatives) written informed consent.

Exclusion Criteria

  • Baseline visit can not be performed between the second and tenth postoperative day.
  • Milk protein allergy
  • Patients with conservative treatment for hip fracture
  • Serum calcium adjusted for albumin of \> 2.6 mmol/L
  • Pathologic fracture in the last year (except for fractures due to osteoporosis)
  • Chemo therapy / Radiation /antihormonal therapy due to cancer in the last year
  • Treatment which has an effect on calcium metabolism (e.g. PTH, calcitonin, chronic cortisone intake \> 5mg/day in the last 12 months (except for inhalation and sporadic infiltration))
  • Oral vitamin D intake of more than 1000 IU per day during the last 3 months before the study
  • Unwilling to stop multi-vitamin, calcium supplementation, and vitamin D supplementation during the trial (maximal calcium supplement intake 250mg/d; no additional vitamin D supplementation). We will inform the treating physician that we initiated vitamin D supplementation as standard of care.
  • Severe visual or hearing impairment

Outcomes

Primary Outcomes

The Short Physical Performance Battery (SPPB)

Time Frame: 6 months

Secondary Outcomes

  • Quality of Life(6 months)
  • Muscle strength(6 months)
  • Nutritional status(6 months)

Study Sites (1)

Loading locations...

Similar Trials